Citations

Showing 10 of 108162 citations.

Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival
Bachy, Emmanuel , Cerhan, James R. , Salles, Gilles , Cerhan, James R , Salles, Gilles A , Bachy, Emmanuel

Mayo Clinic

Blood Advances | March 17, 2021 | Volume: 5 | Issue: 6 | Pages: 1729-1732

10.1182/bloodadvances.2020003797 | PMID 33729455 Get It

Progressive Papular Eruption of the Distal Upper Extremities in a Patient With Asymptomatic Papules
Hobbs, Misty M. , Hall, Matthew J. , Sluzevich, Jason C. , Sluzevich, Jason C , Hall, Matthew

Mayo Clinic

JAMA Dermatology | March 17, 2021 | Volume: 157 | Issue: 5 | Pages: 591

10.1001/jamadermatol.2021.0188 | PMID 33729442 Get It

Utility of mismatch repair protein expression screening via an endoscopic ultrasound assessment of treatment-naive pancreas ductal adenocarcinoma
Paredes, Ana García García de , Graham, Rondell P. , Levy, Michael J. , Rajan, Elizabeth , Zhang, Lizhi , Gleeson, Ferga C. , Garcia Garcia de Paredes, Ana , McWilliams, Robert R. , Gleeson, Ferga C , Graham, Rondell P

Mayo Clinic

Gut | March 17, 2021 | Volume: 71 | Issue: 1 | Pages: 219-221

10.1136/gutjnl-2021-324460 | PMID 33731370 Get It

QIM21-078: Women Representation in Clinical Practice Guidelines (CPGs) Among Major Cancer Organizations
Chengappa, Madhuri, Poonacha, Thejaswi , Desai, Aakash , Go, Ronald S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 17, 2021 | Volume: 19 | Issue: 3.5 | Pages: QIM21-078

10.6004/jnccn.2020.7788 Get It

CLO21-016: Incidence, Risk Factors, and Prognostic Implications of Peri-Transplant Orthostatic Hypotension in Patients With Multiple Myeloma
Low, Soon Khai , Close, Sara, Schlossman, Robert, Laubach, Jacob P. , Glotzbecker, Brett, Richardson, Paul, Ho, Matthew , Moscvin, Maria , Bianchi, Giada

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 17, 2021 | Volume: 19 | Issue: 3.5 | Pages: CLO21-016

10.6004/jnccn.2020.7776 Get It

Coordinated signaling of activating transcription factor 6α and inositol-requiring enzyme 1α regulates hepatic stellate cell-mediated fibrogenesis in mice
Xue, Fei , Lu, Jianwen, Buchl, Samuel C. , Sun, Liankang , Shah, Vijay H. , Malhi, Harmeet , Maiers, Jessica L. , Malhi, Harmeet

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | March 17, 2021 | Volume: 320 | Issue: 5 | Pages: G864-G879

10.1152/ajpgi.00453.2020 | PMID 33728997 Get It

ATF6α is a critical driver of hepatic stellate cell (HSC) activation in vitro. HSC-specific deletion of Atf6a limits fibrogenesis in vivo despite increased IRE1α signaling. Conditional deletion of Ire1α from HSCs limits fibrogenic gene transcription without impacting overall fibrosis. This could be due in part to observed upregulation of the ATF6α pathway. Dual loss of Atf6a and Ire1a from HSCs worsens fibrosis in vivo through enhanced HSC activation.
Contrast-Enhanced Mammography for Newly Diagnosed Breast Cancer in Women With Breast Augmentation: Preliminary Findings
Pockaj, Barbara A. , Pizzitola, Victor J. , Giurescu, Marina E., Lorans, Roxanne, Eversman, William G. , Carnahan, Molly B. , Pockaj, Barbara, Pizzitola, Victor, Eversman, William, Sharpe, Richard E. , Cronin, Patricia A. , Patel, Bhavika

Mayo Clinic

American Journal of Roentgenology | March 17, 2021 | Volume: 217 | Issue: 4 | Pages: 855-856

10.2214/ajr.20.25341 | PMID 33728971 Get It

Surgical and Transcatheter Mitral Valve Replacement in Mitral Annular Calcification: A Systematic Review
Alexis, Sophia L. , Malik, Aaqib H. , El‐Eshmawi, Ahmed, George, Isaac , Sengupta, Aditya , Kodali, Susheel , Hahn, Rebecca T. , Khalique, Omar , Zaid, Syed , Bapat, Vinayak , Leon, Martin B. , Tang, Gilbert H.L. , Hahn, Rebecca T , Guerrero, Mayra , Adams, David

Mayo Clinic

Journal of the American Heart Association | March 17, 2021 | Volume: 10 | Issue: 7 | Pages: No page available

10.1161/jaha.120.018514 | PMID 33728929 Get It

Abstract Mitral annular calcification with mitral valve disease is a challenging problem that could necessitate surgical mitral valve replacement (SMVR). Transcatheter mitral valve replacement (TMVR) is emerging as a feasible alternative in high‐risk patients with appropriate anatomy. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to December 25, 2019 for studies discussing SMVR or TMVR in patients with mitral annular calcification; 27 of 1539 articles were selected for final review. TMVR was used in 15 studies. Relevant data were available on 82 patients who underwent hybrid transatrial TMVR, and 354 patients who underwent transapical or transseptal TMVR. Outcomes on SMVR were generally reported as small case series (447 patients from 11 studies); however, 1 large study recently reported outcomes in 9551 patients. Patients who underwent TMVR had a shorter median follow‐up of 9 to 12 months (range, in‐hospital‒19 months) compared with patients with SMVR (54 months; range, in‐hospital‒120 months). Overall, those undergoing TMVR were older and had higher Society of Thoracic Surgeons risk scores. SMVR showed a wide range of early (0%–27%; median 6.3%) and long‐term mortality (0%–65%; median at 1 year, 15.8%; 5 years, 38.8%, 10 years, 62.4%). The median in‐hospital, 30‐day, and 1‐year mortality rates were 16.7%, 22.7%, and 43%, respectively, for transseptal/transapical TMVR, and 9.5%, 20.0%, and 40%, respectively, for transatrial TMVR. Mitral annular calcification is a complex disease and TMVR, with a versatile option of transatrial approach in patients with challenging anatomy, offers a promising alternative to SMVR in high‐risk patients. However, further studies are needed to improve technology, patient selection, operative expertise, and long‐term outcomes.
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Bible, Keith C. , Kebebew, Electron , Brierley, James D. , Brito, Juan P. , Clark, Thomas J. , Foote, Robert L. , Giordano, Thomas J. , Kasperbauer, Jan L. , Newbold, Kate, Rosenthal, M. Sara, Sawka, Anna M. , Shah, Manisha H. , Shaha, Ashok R. , Smallridge, Robert C., Wong-Clark, Carol K., Kasperbauer, Jan , Smallridge, Robert, Brito, Juan P , Cabanillas, Maria E. , Cristofano, Antonio Di , Nikiforov, Yuri E. , Randolph, Gregory William

Mayo Clinic

Thyroid® | March 17, 2021 | Volume: 31 | Issue: 3 | Pages: 337-386

10.1089/thy.2020.0944 | PMID 33728999 Get It

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, and researchers on published evidence relating to the diagnosis and management of ATC. Methods: The specific clinical questions and topics addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of the Task Force members (authors of the guideline). Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations. Results: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, targeted/systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues, including end of life. The guidelines include 31 recommendations and 16 good practice statements. Conclusions: We have developed evidence-based recommendations to inform clinical decision-making in the management of ATC. While all care must be individualized, such recommendations provide, in our opinion, optimal care paradigms for patients with ATC.